15,000 Shares in IQVIA Holdings Inc. $IQV Acquired by Varma Mutual Pension Insurance Co

Varma Mutual Pension Insurance Co bought a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund bought 15,000 shares of the medical research company’s stock, valued at approximately $2,898,000.

Several other hedge funds and other institutional investors have also modified their holdings of the business. BlackRock Inc. acquired a new stake in IQVIA during the 2nd quarter worth about $2,811,292,000. Concurrent Investment Advisors LLC increased its holdings in shares of IQVIA by 36.0% in the 4th quarter. Concurrent Investment Advisors LLC now owns 11,948 shares of the medical research company’s stock valued at $2,693,000 after purchasing an additional 3,161 shares during the period. Focus Partners Advisor Solutions LLC acquired a new position in shares of IQVIA in the 2nd quarter valued at about $976,000. Munich Reinsurance Co Stock Corp in Munich purchased a new stake in shares of IQVIA in the fourth quarter worth approximately $3,444,000. Finally, Nippon Life Global Investors Americas Inc. boosted its holdings in shares of IQVIA by 36.6% during the fourth quarter. Nippon Life Global Investors Americas Inc. now owns 79,400 shares of the medical research company’s stock worth $17,898,000 after purchasing an additional 21,270 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Up 0.1%

IQVIA stock opened at $260.17 on Monday. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. IQVIA Holdings Inc. has a 1-year low of $154.50 and a 1-year high of $260.40. The firm’s fifty day simple moving average is $213.32 and its 200-day simple moving average is $187.21. The company has a market capitalization of $42.82 billion, a P/E ratio of 32.28, a P/E/G ratio of 2.21 and a beta of 1.18.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. The firm had revenue of $4.37 billion during the quarter, compared to analysts’ expectations of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. IQVIA’s revenue for the quarter was up 8.7% on a year-over-year basis. During the same period in the prior year, the company posted $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Sell-side analysts forecast that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA announced that its board has initiated a stock buyback program on Thursday, May 7th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s management believes its shares are undervalued.

Analysts Set New Price Targets

Several research firms have weighed in on IQV. HSBC reiterated a “buy” rating and issued a $240.00 price objective on shares of IQVIA in a research note on Monday, July 6th. Robert W. Baird boosted their price target on shares of IQVIA from $252.00 to $287.00 and gave the company an “outperform” rating in a report on Wednesday, July 29th. Deutsche Bank Aktiengesellschaft set a $240.00 price target on shares of IQVIA in a research note on Thursday, July 9th. Weiss Ratings upgraded IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, July 15th. Finally, Morgan Stanley restated an “equal weight” rating and issued a $200.00 target price (down from $225.00) on shares of IQVIA in a research note on Wednesday, June 17th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, IQVIA presently has an average rating of “Moderate Buy” and an average price target of $241.88.

Insider Buying and Selling

In related news, insider Keriann Cherofsky sold 558 shares of the business’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total value of $136,827.18. Following the completion of the sale, the insider directly owned 2,989 shares in the company, valued at approximately $732,932.69. The trade was a 15.73% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Eric Sherbet sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total value of $1,245,800.00. Following the sale, the insider directly owned 20,999 shares of the company’s stock, valued at $5,232,110.84. The trade was a 19.23% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 12,913 shares of company stock worth $3,098,793. Insiders own 1.70% of the company’s stock.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.